Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab
Cancers · 12.12.2025 · 17 (24) · 3967
DOI: 10.3390/cancers17243967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.12.2025. Verfasst von Ji Hoon Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Liver Research Center, The Catholic University of Korea, Seoul 06591, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Korean government, Internal Research Fund of the Korean Liver Cancer Association.
Abstract (Originalsprache)
Background
Glypican-3 (GPC3) is overexpressed in most hepatocellular carcinoma (HCC) tissues but is absent in normal adult liver. We evaluated whether tumor GPC3 expression is associated with clinical outcomes in patients with advanced HCC treated with atezolizumab–bevacizumab (AB).
Methods
We conducted a single-center retrospective cohort study of 139 patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC who received AB between January 2022 and August 2025. Tumor GPC3 expression was assessed by immunohistochemistry. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was objective response rate (ORR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
Results
Baseline characteristics were largely balanced between GPC3-positive (n = 87) and GPC3-negative (n = 52) groups. Median OS was significantly shorter in patients with GPC3-positive tumors than in those with GPC3-negative tumors (p = 0.006). In multivariable analysis, GPC3 positivity remained independently associated with higher mortality (hazard ratio [HR] 1.77, 95% confidence interval [CI] 1.05–3.00; p = 0.033), along with Child–Pugh class B. PFS did not differ significantly between the groups (p = 0.712). ORR was lower in GPC3-positive tumors than in GPC3-negative tumors (approximately 17–18% vs. ~32%; p = 0.023). Membranous GPC3 localization was associated with inferior OS compared with cytoplasmic or absent expression (p = 0.025).
Conclusions
Tumor GPC3 expression was associated with decreased OS and lower ORR among AB-treated patients with advanced HCC, suggesting potential clinical relevance and may help in risk stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Liver Research Center, The Catholic University of Korea, Seoul 06591, Republic of Korea.
- Department of Gastroenterology and Hepatology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea.
ORCID-Profile: Ji Won Han, Jeong Won Jang, Kwon Yong Tak, Pil Soo Sung
Förderung
- Ministry of Science and ICT
- Korean government
- Internal Research Fund of the Korean Liver Cancer Association
Zitieren
APA
Kim, J. H., Han, J. W., Cho, H. S., Jang, J. W., Tak, K. Y., & Sung, P. S. (2025). Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab. Cancers, 17(24), 3967. https://doi.org/10.3390/cancers17243967
Vancouver
Kim JH, Han JW, Cho HS, Jang JW, Tak KY, Sung PS. Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab. Cancers. 2025;17(24):3967. doi:10.3390/cancers17243967
BibTeX
@article{Kim2025,
author = {Kim, Ji Hoon and Han, Ji Won and Cho, Hee Sun and Jang, Jeong Won and Tak, Kwon Yong and Sung, Pil Soo},
title = {Prognostic Significance of Glypican-3 Expression in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {3967},
doi = {10.3390/cancers17243967}
}
EUVIMED